Simard Elie, Jin Denan, Takai Shinji, Miyazaki Mizuo, Brochu Isabelle, D'Orléans-Juste Pedro
Département de Pharmacologie, Facultéde médecine et des Sciences de Santé, Universitéde Sherbrooke, Sherbrooke, Quebec, Canada.
J Pharmacol Exp Ther. 2009 Feb;328(2):540-8. doi: 10.1124/jpet.108.142992. Epub 2008 Nov 5.
The aim of this study was to identify the role of chymase in the conversion of exogenously administered Big endothelin-1 in the mouse in vivo. Real-time polymerase chain reaction analysis detected mRNA of mucosal mast cell chymases 4 and 5, endothelin-converting enzyme 1a, and neutral endopeptidase 24.11 in pulmonary, cardiac, and aorta homogenates derived from C57BL/6J mice, with the latter tissue expressing the highest levels of both chymase isoforms. Furthermore, hydrolysis of a fluorogenic peptide substrate, Suc-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin, was sensitive to the chymase inhibitors Suc-Val-Pro-Phe(P)(OPh)(2) (200 microM) and chymostatin [(S)-1-carboxy-2-phenylethyl]-carbamoyl-alpha-[2-iminohexahydro-4(S)-pyrimidyl]-(S)-Gly-X-Phe-al, where X can be the amino acid Leu, Val, or Ile) (100 microM) in supernatants extracted from the same tissue homogenates. In anesthetized mice, Big endothelin-1, endothelin-1 (1-31), and endothelin-1 triggered pressor responses (ED(50)s, 0.67, 0.89, and 0.16 nmol/kg) that were all reduced or potentiated by selective endothelin ET(A) or ET(B) receptor antagonists, respectively, BQ-123 (cyclo[D-Asp-Pro-D-Val-Leu-D-Trp]) or BQ-788 (N-[N-[N-[(2,6-dimethyl-1-piperidinyl)carbonyl]-4-methyl-l-leucyl]-1-(methoxycarbonyl)-D-tryptophyl]-d-norleucine sodium salt), each at 1 mg/kg. The pressor responses to big endothelin-1 were significantly reduced by the neutral endopeptidase inhibitor thiorphan (dl-3-mercapto-2-benzylpropanoylglycine) (1 mg/kg) or the endothelin-converting enzyme inhibitor CGS 35066 [alpha-[(S)-(phosphonomethyl)amino]-3-dibenzofuranopropanoic acid] (0.1 mg/kg). In contrast, the responses to endothelin-1 (1-31) were abolished by thiorphan but unaffected by CGS 35066. In addition, Suc-Val-Pro-Phe(P)(OPh)(2) (20-40 mg/kg) reduced, by more than 60%, the hemodynamic response to big endothelin-1 but not to endothelin-1 (1-31) and endothelin-1. Finally, intravenous administration of big endothelin-1 induced Suc-Val-Pro-Phe(P)-(OPh)(2)-sensitive increases in plasma-immunoreactive levels of endothelin-1 (1-31) and endothelin-1. The present study suggests that chymase plays a pivotal role in the conversion and cardiovascular properties of big endothelin-1 in vivo.
本研究的目的是确定糜酶在小鼠体内外源性给予的大内皮素-1转化过程中的作用。实时聚合酶链反应分析在源自C57BL/6J小鼠的肺、心脏和主动脉匀浆中检测到黏膜肥大细胞糜酶4和5、内皮素转化酶1a以及中性内肽酶24.11的mRNA,后一种组织中两种糜酶同工型的表达水平最高。此外,荧光肽底物Suc-Leu-Leu-Val-Tyr-7-氨基-4-甲基香豆素的水解对来自相同组织匀浆提取物上清液中的糜酶抑制剂Suc-Val-Pro-Phe(P)(OPh)(2)(200 microM)和抑糜酶肽[(S)-1-羧基-2-苯乙基]-氨基甲酰-α-[2-亚氨基六氢-4(S)-嘧啶基]-(S)-甘氨酸-X-苯丙氨酸-al(其中X可以是氨基酸亮氨酸、缬氨酸或异亮氨酸)(100 microM)敏感。在麻醉的小鼠中,大内皮素-1、内皮素-1(1-31)和内皮素-1引发的升压反应(半数有效剂量分别为0.67、0.89和0.16 nmol/kg)分别被选择性内皮素ET(A)或ET(B)受体拮抗剂BQ-123(环[D-天冬氨酸-脯氨酸-D-缬氨酸-亮氨酸-D-色氨酸])或BQ-788(N-[N-[N-[(2,6-二甲基-1-哌啶基)羰基]-4-甲基-L-亮氨酰]-1-(甲氧羰基)-D-色氨酰]-D-正亮氨酸钠盐)(均为1 mg/kg)降低或增强。中性内肽酶抑制剂硫磷酰胺(dl-3-巯基-2-苄基丙酰甘氨酸)(1 mg/kg)或内皮素转化酶抑制剂CGS 35066 [α-[(S)-(膦酰甲基)氨基]-3-二苯并呋喃丙酸](0.1 mg/kg)可显著降低对大内皮素-1的升压反应。相反,硫磷酰胺可消除对内皮素-1(1-31)的反应,但CGS 35066对其无影响。此外,Suc-Val-Pro-Phe(P)(OPh)(2)(20 - 40 mg/kg)可使对大内皮素-1的血流动力学反应降低60%以上,但对内皮素-1(1-31)和内皮素-1无此作用。最后,静脉注射大内皮素-1可诱导血浆中内皮素-1(1-31)和内皮素-1的免疫反应性水平出现Suc-Val-Pro-Phe(P)-(OPh)(2)敏感的升高。本研究表明,糜酶在体内大内皮素-1的转化和心血管特性中起关键作用。